Knopf et al., 2015 - Google Patents

S. mansoni trapping in lungs contributes to resistance to reinfection

Knopf et al., 2015

View HTML
Document ID
13105025788621239627
Author
Knopf P
Suri P
Publication year
Publication venue
Frontiers in Immunology

External Links

Snippet

Worm transplantation studies show that physiological and reproductive status of the worm is influenced by the microenvironment of the host and critical for vaccine design. Worm migration studies in rats with 75Se-methionine labeled cercariae demonstrated that …
Continue reading at www.frontiersin.org (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Similar Documents

Publication Publication Date Title
Oliveira et al. A sand fly salivary protein vaccine shows efficacy against vector-transmitted cutaneous leishmaniasis in nonhuman primates
Kumar et al. Cutting edge: CD1d deficiency impairs murine host defense against the spirochete, Borrelia burgdorferi
Vacchio et al. A ThPOK-LRF transcriptional node maintains the integrity and effector potential of post-thymic CD4+ T cells
Seid et al. Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease
Haddadi et al. Mucosal-pull induction of lung-resident memory CD8 T cells in parenteral TB vaccine-primed hosts requires cognate antigens and CD4 T cells
Gorringe et al. Bordetella pertussis fimbriae (Fim): relevance for vaccines
Kupz et al. Cellular requirements for systemic control of Salmonella enterica serovar Typhimurium infections in mice
Gong et al. Animal models of tuberculosis vaccine research: an important component in the fight against tuberculosis
Selvapandiyan et al. Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis
Volpedo et al. Centrin-deficient Leishmania mexicana confers protection against New World cutaneous leishmaniasis
Hamilton et al. MHC class Ia–restricted memory T cells inhibit expansion of a nonprotective MHC class Ib (H2-M3)–restricted memory response
Rodríguez-Martín et al. The interplay between bluetongue virus infections and adaptive immunity
Liang et al. RHΔ gra17 Δ npt1 strain of Toxoplasma gondii elicits protective immunity against acute, chronic and congenital toxoplasmosis in mice
Lu et al. Characterization of Treponema pallidum dissemination in C57BL/6 mice
Su et al. Mycobacterium tuberculosis latent antigen Rv2029c from the multistage DNA vaccine A39 drives TH1 responses via TLR-mediated macrophage activation
Torina et al. Immune response to Tick-Borne hemoparasites: Host adaptive immune response mechanisms as potential targets for therapies and vaccines
Wu et al. Live-attenuated ME49Δ cdpk3 strain of Toxoplasma gondii protects against acute and chronic toxoplasmosis
Romano et al. A structural view at vaccine development against M. tuberculosis
Araiza-Villanueva et al. Proteomic analysis of membrane blebs of Brucella abortus 2308 and RB51 and their evaluation as an acellular vaccine
Fernández et al. Protective efficacy in a Hamster model of a multivalent vaccine for human visceral Leishmaniasis (MuLeVaClin) consisting of the KMP11, LEISH-F3+, and LJL143 antigens in virosomes, plus GLA-SE adjuvant
Fan et al. Host responses to live-attenuated ASFV (HLJ/18–7GD)
Hove et al. Targeted mutagenesis in Anaplasma marginale to define virulence and vaccine development against bovine anaplasmosis
Gimenez et al. A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three Pv CSP alleles
Kupz et al. Treatment of mice with S4B6 IL-2 complex prevents lethal toxoplasmosis via IL-12-and IL-18-dependent interferon-gamma production by non-CD4 immune cells
Vasilyev et al. Enhancement of the local CD8+ T-Cellular immune response to Mycobacterium Tuberculosis in BCG-primed mice after intranasal administration of influenza vector vaccine carrying TB10. 4 and HspX Antigens